{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:16:32Z","timestamp":1790741792597,"version":"4.1.0"},"reference-count":33,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.3201\/eid2809.220092","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T11:50:24Z","timestamp":1660218624000},"page":"1814-1823","source":"Crossref","is-referenced-by-count":17,"title":["Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010\u20132016"],"prefix":"10.3201","volume":"28","author":[{"given":"Jonathon R.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Placide","family":"Nsengiyumva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie Y.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel","family":"Khadawardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry K.-H.","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Oxlade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden","family":"Rasberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Romanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha F.","family":"Sabur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashna","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Brode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2809.220092-202208171203-R1","unstructured":"Public Health Agency of Canada. Canadian tuberculosis standards. Seventh edition. Ottawa (Ontario): Government of Canada; 2014."},{"key":"key-10.3201\/eid2809.220092-202208171203-R2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.14745\/ccdr.v45i23a04","article-title":"Tuberculosis in Canada: 2017.","volume":"45","author":"LaFreniere","year":"2019","journal-title":"Can Commun Dis Rep"},{"key":"key-10.3201\/eid2809.220092-202208171203-R3","unstructured":"Kanatami IT. Inuit Tuberculosis Elimination Framework. 2018 [cited 2021 Jul 29]. https:\/\/www.itk.ca\/wp-content\/uploads\/2018\/12\/FINAL-ElectronicEN-Inuit-TB-Elimination-Framework.pdf"},{"key":"key-10.3201\/eid2809.220092-202208171203-R4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1503\/cmaj.131025","article-title":"Screening immigrants for latent tuberculosis: do we have the resources?","volume":"186","author":"Campbell","year":"2014","journal-title":"CMAJ"},{"key":"key-10.3201\/eid2809.220092-202208171203-R5","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th edition. New York: Oxford University Press; 2015."},{"key":"key-10.3201\/eid2809.220092-202208171203-R6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/BF03405248","article-title":"Costs for tuberculosis care in Canada.","volume":"99","author":"Menzies","year":"2008","journal-title":"Can J Public Health"},{"key":"key-10.3201\/eid2809.220092-202208171203-R7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults.","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2809.220092-202208171203-R8","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2809.220092-202208171203-R9","doi-asserted-by":"crossref","unstructured":"Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J,  Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018 02;379(5):454\u201363.","DOI":"10.1056\/NEJMoa1714284"},{"key":"key-10.3201\/eid2809.220092-202208171203-R10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.","volume":"6","author":"Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"key":"key-10.3201\/eid2809.220092-202208171203-R11","doi-asserted-by":"publisher","first-page":"1901467","DOI":"10.1183\/13993003.01467-2019","article-title":"Standardised shorter regimens versus individualised longer regimens for multidrug-resistant TB.","volume":"55","author":"Abidi","year":"2020","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid2809.220092-202208171203-R12","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment: drug-resistant tuberculosis treatment. 2020 [cited 2020 Jul 31]. https:\/\/www.who.int\/publications\/i\/item\/9789240007048"},{"key":"key-10.3201\/eid2809.220092-202208171203-R13","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1093\/cid\/ciaa1822","article-title":"Comparing the diagnostic performance of QFT-Plus to other tests of latent tuberculosis infection: a systematic review and meta-analysis.","volume":"73","author":"Oh","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2809.220092-202208171203-R14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4097\/kjae.2017.70.2.144","article-title":"Central limit theorem: the cornerstone of modern statistics.","volume":"70","author":"Kwak","year":"2017","journal-title":"Korean J Anesthesiol"},{"key":"key-10.3201\/eid2809.220092-202208171203-R15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7326\/M19-3741","article-title":"Health system costs of treating latent tuberculosis infection with four months of rifampin versus nine months of isoniazid in different settings.","volume":"173","author":"Bastos","year":"2020","journal-title":"Ann Intern Med"},{"key":"key-10.3201\/eid2809.220092-202208171203-R16","unstructured":"R Core Team. R: a language and environment for statistical computing. 2021 [cited 2021 Jul 27]. https:\/\/www.r-project.org"},{"key":"key-10.3201\/eid2809.220092-202208171203-R17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4.","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"key-10.3201\/eid2809.220092-202208171203-R18","unstructured":"Bank of Canada. Inflation calculator. 2021 [cited 2021 Dec 8]. https:\/\/www.bankofcanada.ca\/rates\/related\/inflation-calculator"},{"key":"key-10.3201\/eid2809.220092-202208171203-R19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.14745\/ccdr.v44i11a04","article-title":"Tuberculosis drug resistance in Canada: 2017.","volume":"44","author":"LaFreniere","year":"2018","journal-title":"Can Commun Dis Rep"},{"key":"key-10.3201\/eid2809.220092-202208171203-R20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3201\/eid2005.131037","article-title":"Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.","volume":"20","author":"Marks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid2809.220092-202208171203-R21","unstructured":"Centers for Disease Control and Prevention. CDC estimates for TB treatment costs (in 2020 U.S. dollars). 2021 [cited 2022 Jan 14]. https:\/\/www.cdc.gov\/tb\/publications\/infographic\/appendix.htm"},{"key":"key-10.3201\/eid2809.220092-202208171203-R22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/17441692.2019.1663361","article-title":"Opportunities for community health workers to contribute to global efforts to end tuberculosis.","volume":"15","author":"Sinha","year":"2020","journal-title":"Glob Public Health"},{"key":"key-10.3201\/eid2809.220092-202208171203-R23","unstructured":"McKenna L. The price of bedaquiline. 2018 [cited 2021 Dec 8]. https:\/\/www.treatmentactiongroup.org\/wp-content\/uploads\/2018\/10\/reality_check_bedaquiline_10_16_18.pdf"},{"key":"key-10.3201\/eid2809.220092-202208171203-R24","unstructured":"Stop TB. Partnership. Global Drug Facility July 2022 Medicines Catalog. 2022 [cited 2022 Aug 2]. https:\/\/www.stoptb.org\/sites\/default\/files\/gdfmedicinescatalog_1.pdf"},{"key":"key-10.3201\/eid2809.220092-202208171203-R25","doi-asserted-by":"publisher","first-page":"e004143","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"key":"key-10.3201\/eid2809.220092-202208171203-R26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"key-10.3201\/eid2809.220092-202208171203-R27","unstructured":"World Health Organization. Rapid communication: Key changes to the treatment of drug-resistant tuberculosis. 2022 [cited 2022 May 3]. https:\/\/www.who.int\/publications\/i\/item\/WHO-UCN-TB-2022-2"},{"key":"key-10.3201\/eid2809.220092-202208171203-R28","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Tuberculosis Trials Consortium. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis.","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2809.220092-202208171203-R29","doi-asserted-by":"publisher","first-page":"e047514","DOI":"10.1136\/bmjopen-2020-047514","article-title":"Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.","volume":"11","author":"Pease","year":"2021","journal-title":"BMJ Open"},{"key":"key-10.3201\/eid2809.220092-202208171203-R30","doi-asserted-by":"publisher","first-page":"e002187","DOI":"10.1136\/bmjgh-2019-002187","article-title":"Patient pathways of tuberculosis care-seeking and treatment: an individual-level analysis of National Health Insurance data in Taiwan.","volume":"5","author":"Ku","year":"2020","journal-title":"BMJ Glob Health"},{"key":"key-10.3201\/eid2809.220092-202208171203-R31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/thoraxjnl-2020-215338","article-title":"The long term effect of pulmonary tuberculosis on income and employment in a low income, urban setting.","volume":"76","author":"Meghji","year":"2021","journal-title":"Thorax"},{"key":"key-10.3201\/eid2809.220092-202208171203-R32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41598-021-04345-x","article-title":"A systematic review and meta-analysis of the catastrophic costs incurred by tuberculosis patients.","volume":"12","author":"Ghazy","year":"2022","journal-title":"Sci Rep"},{"key":"key-10.3201\/eid2809.220092-202208171203-R33","doi-asserted-by":"publisher","first-page":"236","DOI":"10.14745\/ccdr.v43i11a05","article-title":"Tuberculosis drug resistance in Canada: 2006-2016.","volume":"43","author":"Gallant","year":"2017","journal-title":"Can Commun Dis Rep"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/9\/22-0092_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T12:56:43Z","timestamp":1732971403000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/9\/22-0092_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2809.220092","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}